$PODD
INSULET CORP

2013 Q1 Form 10-K Financial Statement

#000119312513083670 Filed on February 28, 2013

View on sec.gov

Income Statement

Concept 2013 Q1 2012 Q3 2012 Q2
Revenue $57.36M $54.75M $51.04M
YoY Change 20.11% 22.78% 58.44%
Cost Of Revenue $32.20M $30.36M $28.70M
YoY Change 17.27% 16.63% 62.42%
Gross Profit $25.16M $24.39M $22.33M
YoY Change 23.94% 31.4% 53.6%
Gross Profit Margin 43.86% 44.55% 43.76%
Selling, General & Admin $26.97M $26.30M $26.33M
YoY Change 4.68% 11.02% 16.39%
% of Gross Profit 107.2% 107.84% 117.9%
Research & Development $4.396M $6.559M $6.521M
YoY Change -19.07% 41.42% -4.55%
% of Gross Profit 17.48% 26.89% 29.2%
Depreciation & Amortization $2.904M $2.590M $2.660M
YoY Change 2.11% -8.48% 57.4%
% of Gross Profit 11.54% 10.62% 11.91%
Operating Expenses $31.36M $32.86M $32.85M
YoY Change 0.55% 16.0% 11.53%
Operating Profit -$6.206M -$8.471M -$10.52M
YoY Change -43.04% -13.28% -29.47%
Interest Expense $0.00 -$3.900M -$3.900M
YoY Change -100.0% 2.63% -13.33%
% of Operating Profit
Other Income/Expense, Net -$4.328M -$3.918M -$3.888M
YoY Change 12.74% 3.27% -13.75%
Pretax Income -$10.53M -$12.39M -$14.41M
YoY Change -28.51% -8.65% -25.83%
Income Tax $131.0K $28.00K $69.00K
% Of Pretax Income
Net Earnings -$10.67M -$12.42M -$14.48M
YoY Change -27.84% -8.44% 79.07%
Net Earnings / Revenue -18.59% -22.68% -28.36%
Basic Earnings Per Share
Diluted Earnings Per Share -$201.5K -$258.3K -$303.3K
COMMON SHARES
Basic Shares Outstanding 53.10M shares 47.99M shares 47.77M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2013 Q1 2012 Q3 2012 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $148.1M $63.40M $70.10M
YoY Change 78.43% -38.92% -34.3%
Cash & Equivalents $148.1M $63.44M $70.14M
Short-Term Investments
Other Short-Term Assets $6.400M $5.600M $4.300M
YoY Change 48.84% 51.35% -10.42%
Inventory $9.199M $15.09M $16.43M
Prepaid Expenses
Receivables $31.11M $30.15M $25.59M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $194.8M $114.2M $116.5M
YoY Change 51.89% -17.86% -21.86%
LONG-TERM ASSETS
Property, Plant & Equipment $24.98M $24.91M $21.42M
YoY Change 25.24% 36.12% 33.06%
Goodwill $37.54M $37.54M $37.54M
YoY Change 0.0% 0.09% -1.39%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $2.056M $2.333M $2.503M
YoY Change -22.33% -16.68% -19.26%
Total Long-Term Assets $86.14M $89.14M $87.21M
YoY Change -1.51% -0.14% -2.77%
TOTAL ASSETS
Total Short-Term Assets $194.8M $114.2M $116.5M
Total Long-Term Assets $86.14M $89.14M $87.21M
Total Assets $280.9M $203.4M $203.7M
YoY Change 30.24% -10.93% -14.69%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $8.544M $16.22M $13.69M
YoY Change -46.95% 88.56% 45.61%
Accrued Expenses $18.02M $17.82M $13.54M
YoY Change 39.53% 39.19% 10.04%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $14.73M $14.13M $13.85M
YoY Change
Total Short-Term Liabilities $42.98M $49.34M $43.14M
YoY Change 31.92% 98.96% 62.18%
LONG-TERM LIABILITIES
Long-Term Debt $106.2M $101.5M $99.38M
YoY Change -4.2% -4.5% -4.62%
Other Long-Term Liabilities $2.186M $2.070M $2.068M
YoY Change 7.16% -16.57% -18.07%
Total Long-Term Liabilities $108.4M $103.6M $101.5M
YoY Change -4.0% 4075.21% 3919.41%
TOTAL LIABILITIES
Total Short-Term Liabilities $42.98M $49.34M $43.14M
Total Long-Term Liabilities $108.4M $103.6M $101.5M
Total Liabilities $151.4M $152.9M $144.6M
YoY Change 4.05% 14.5% 8.46%
SHAREHOLDERS EQUITY
Retained Earnings -$492.2M -$471.4M -$458.9M
YoY Change 10.74% 13.49% 14.23%
Common Stock $53.00K $48.00K $48.00K
YoY Change 10.42%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $129.5M $50.45M $59.09M
YoY Change
Total Liabilities & Shareholders Equity $280.9M $203.4M $203.7M
YoY Change 30.24% -10.93% -14.69%

Cashflow Statement

Concept 2013 Q1 2012 Q3 2012 Q2
OPERATING ACTIVITIES
Net Income -$10.67M -$12.42M -$14.48M
YoY Change -27.84% -8.44% 79.07%
Depreciation, Depletion And Amortization $2.904M $2.590M $2.660M
YoY Change 2.11% -8.48% 57.4%
Cash From Operating Activities -$1.200M -$3.450M -$11.12M
YoY Change -86.52% 315.66% 22.47%
INVESTING ACTIVITIES
Capital Expenditures $1.069M -$4.690M -$2.550M
YoY Change -37.08% 42.99% -4.14%
Acquisitions
YoY Change
Other Investing Activities $0.00 $0.00
YoY Change -100.0%
Cash From Investing Activities -$1.069M -$4.690M -$2.550M
YoY Change -37.08% 43.43% -93.71%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $94.36M
YoY Change 14806.95%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities $93.04M 1.430M 810.0K
YoY Change -26912.97% 21.19% -98.44%
NET CHANGE
Cash From Operating Activities -$1.200M -3.450M -11.12M
Cash From Investing Activities -$1.069M -4.690M -2.550M
Cash From Financing Activities $93.04M 1.430M 810.0K
Net Change In Cash $90.77M -6.710M -12.86M
YoY Change -929.04% 129.79% -669.03%
FREE CASH FLOW
Cash From Operating Activities -$1.200M -$3.450M -$11.12M
Capital Expenditures $1.069M -$4.690M -$2.550M
Free Cash Flow -$2.269M $1.240M -$8.570M
YoY Change -78.6% -49.39% 33.49%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2013Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
53104565 shares
CY2009Q3 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
1900000
CY2009Q3 us-gaap Sale Of Stock Price Per Share
SaleOfStockPricePerShare
9.63
CY2009Q3 podd Fair Value Of Common Stock On Transaction Date
FairValueOfCommonStockOnTransactionDate
10.28
CY2011Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
5991000
CY2011Q2 us-gaap Goodwill
Goodwill
38066000
CY2011Q2 us-gaap Stockholders Equity
StockholdersEquity
105438000
CY2011Q2 us-gaap Liabilities
Liabilities
133312000
CY2011Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
2524000
CY2011Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-401783000
CY2011Q2 us-gaap Assets
Assets
238750000
CY2011Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
238750000
CY2011Q2 us-gaap Assets Current
AssetsCurrent
149055000
CY2011Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4874000
CY2011Q3 us-gaap Goodwill
Goodwill
37503000
CY2011Q3 us-gaap Stockholders Equity
StockholdersEquity
94779000
CY2011Q3 us-gaap Liabilities
Liabilities
133561000
CY2011Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
2481000
CY2011Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-415345000
CY2011Q3 us-gaap Assets
Assets
228340000
CY2011Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
228340000
CY2011Q3 us-gaap Assets Current
AssetsCurrent
139078000
CY2012Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4313000
CY2012Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
215681000
CY2012Q1 us-gaap Goodwill
Goodwill
37536000
CY2012Q1 us-gaap Stockholders Equity
StockholdersEquity
70217000
CY2012Q1 us-gaap Liabilities
Liabilities
145464000
CY2012Q1 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
2040000
CY2012Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-444464000
CY2012Q1 us-gaap Assets
Assets
215681000
CY2012Q1 us-gaap Assets Current
AssetsCurrent
128219000
CY2012Q2 dei Entity Public Float
EntityPublicFloat
956900000
CY2012Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4304000
CY2012Q2 us-gaap Goodwill
Goodwill
37536000
CY2012Q2 us-gaap Stockholders Equity
StockholdersEquity
59089000
CY2012Q2 us-gaap Liabilities
Liabilities
144590000
CY2012Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
2068000
CY2012Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-458940000
CY2012Q2 us-gaap Assets
Assets
203679000
CY2012Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
203679000
CY2012Q2 us-gaap Assets Current
AssetsCurrent
116465000
CY2012Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
5567000
CY2012Q3 us-gaap Goodwill
Goodwill
37536000
CY2012Q3 us-gaap Stockholders Equity
StockholdersEquity
50452000
CY2012Q3 us-gaap Liabilities
Liabilities
152929000
CY2012Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
2070000
CY2012Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-471357000
CY2012Q3 us-gaap Assets
Assets
203381000
CY2012Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
203381000
CY2012Q3 us-gaap Assets Current
AssetsCurrent
114244000
CY2009Q1 us-gaap Line Of Credit Facility Maximum Borrowing Capacity
LineOfCreditFacilityMaximumBorrowingCapacity
60000000
CY2009Q1 us-gaap Deferred Finance Costs Noncurrent Gross
DeferredFinanceCostsNoncurrentGross
3000000
CY2009Q4 us-gaap Stockholders Equity
StockholdersEquity
61910000
CY2009Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
127996000
CY2010Q4 us-gaap Deferred Rent Credit
DeferredRentCredit
0
CY2010Q4 us-gaap Stockholders Equity
StockholdersEquity
66231000
CY2010Q4 us-gaap Product Warranty Accrual
ProductWarrantyAccrual
1873000
CY2010Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
113274000
CY2010Q4 us-gaap Sale Of Stock Price Per Share
SaleOfStockPricePerShare
13.27
CY2011Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3652000
CY2011Q4 us-gaap Goodwill
Goodwill
37536000
CY2011Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
42355000
CY2011Q4 us-gaap Deferred Tax Assets Net Current
DeferredTaxAssetsNetCurrent
900000
CY2011Q4 us-gaap Acquired Finite Lived Intangible Asset Amount
AcquiredFiniteLivedIntangibleAssetAmount
32900000
CY2011Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
931000
CY2011Q4 us-gaap Product Warranty Accrual Classified Current
ProductWarrantyAccrualClassifiedCurrent
940000
CY2011Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
129223000
CY2011Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
-48000
CY2011Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
2727000
CY2011Q4 us-gaap Deferred Rent Credit
DeferredRentCredit
0
CY2011Q4 us-gaap Stockholders Equity
StockholdersEquity
82735000
CY2011Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
29002000
CY2011Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2011Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1279000
CY2011Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2011Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
6141000
CY2011Q4 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
50210000
CY2011Q4 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
100000
CY2011Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
47504131 shares
CY2011Q4 us-gaap Deferred Tax Liabilities Goodwill And Intangible Assets Goodwill
DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill
48000
CY2011Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
2813000
CY2011Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
359000
CY2011Q4 us-gaap Product Warranty Accrual
ProductWarrantyAccrual
1960000
CY2011Q4 us-gaap Deferred Tax Liabilities Deferred Expense Other Capitalized Costs
DeferredTaxLiabilitiesDeferredExpenseOtherCapitalizedCosts
657000
CY2011Q4 us-gaap Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets
DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
10696000
CY2011Q4 us-gaap Liabilities
Liabilities
138587000
CY2011Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
11418000
CY2011Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
200000
CY2011Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
141000000
CY2011Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
2582000
CY2011Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
4040000
CY2011Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
2052000
CY2011Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2011Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
7352000
CY2011Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-429684000
CY2011Q4 us-gaap Assets
Assets
221322000
CY2011Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
11.02
CY2011Q4 us-gaap Deferred Tax Liabilities Noncurrent
DeferredTaxLiabilitiesNoncurrent
900000
CY2011Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
23190000
CY2011Q4 us-gaap Inventory Net
InventoryNet
11838000
CY2011Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2011Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
221322000
CY2011Q4 us-gaap Long Term Debt
LongTermDebt
108540000
CY2011Q4 us-gaap Product Warranty Accrual Noncurrent
ProductWarrantyAccrualNoncurrent
1020000
CY2011Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
93955000
CY2011Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
32900000
CY2011Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
47504131 shares
CY2011Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards State And Local
DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal
277500000
CY2011Q4 us-gaap Deferred Finance Costs Noncurrent Net
DeferredFinanceCostsNoncurrentNet
2597000
CY2011Q4 us-gaap Deferred Revenue
DeferredRevenue
2700000
CY2011Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
7021000
CY2011Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Allowance For Doubtful Accounts
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts
2589000
CY2011Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
13064000
CY2011Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
3528000
CY2011Q4 us-gaap Accounts Receivable Gross Current
AccountsReceivableGrossCurrent
30211000
CY2011Q4 us-gaap Liabilities Current
LiabilitiesCurrent
27995000
CY2011Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2814591 shares
CY2011Q4 us-gaap Common Stock Value
CommonStockValue
48000
CY2011Q4 us-gaap Deferred Tax Liabilities Deferred Expense Deferred Financing Costs
DeferredTaxLiabilitiesDeferredExpenseDeferredFinancingCosts
18535000
CY2011Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2011Q4 us-gaap Interest Payable Current
InterestPayableCurrent
258000
CY2011Q4 us-gaap Taxes Payable Current
TaxesPayableCurrent
247000
CY2011Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
3898000
CY2011Q4 us-gaap Assets Current
AssetsCurrent
132635000
CY2011Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
7951000
CY2011Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards Domestic
DeferredTaxAssetsOperatingLossCarryforwardsDomestic
372300000
CY2011Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2011Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
159111000
CY2011Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2011Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2011Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
22933000
CY2011Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
19422000
CY2011Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
512371000
CY2011Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
108540000
CY2011Q4 podd Deferred Tax Assets Depreciation And Amortization
DeferredTaxAssetsDepreciationAndAmortization
1988000
CY2011Q4 podd Deferred Tax Liabilities Gross
DeferredTaxLiabilitiesGross
29936000
CY2011Q4 podd Accrued Training Current
AccruedTrainingCurrent
377000
CY2011Q4 podd Deferred Tax Assets Start Up Costs
DeferredTaxAssetsStartUpCosts
2142000
CY2011Q4 podd Accrued Supplier Charges
AccruedSupplierCharges
1009000
CY2012Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4482000
CY2012Q4 us-gaap Goodwill
Goodwill
37536000
CY2012Q4 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
1511000
CY2012Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
53349000
CY2012Q4 us-gaap Deferred Tax Assets Net Current
DeferredTaxAssetsNetCurrent
500000
CY2012Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
25000
CY2012Q4 us-gaap Product Warranty Accrual Classified Current
ProductWarrantyAccrualClassifiedCurrent
863000
CY2012Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
145927000
CY2012Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
-139000
CY2012Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
2202000
CY2012Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
3251
CY2012Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
1539729 shares
CY2012Q4 us-gaap Deferred Rent Credit
DeferredRentCredit
0
CY2012Q4 us-gaap Stockholders Equity
StockholdersEquity
44176000
CY2012Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
22963000
CY2012Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2012Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
2875000
CY2012Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
15763000
CY2012Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2012Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
2190
CY2012Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
6789000
CY2012Q4 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
40591000
CY2012Q4 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
100000
CY2012Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
11.06
CY2012Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
19463000
CY2012Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
48359063 shares
CY2012Q4 us-gaap Deferred Tax Liabilities Goodwill And Intangible Assets Goodwill
DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill
139000
CY2012Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
2069000
CY2012Q4 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
45000
CY2012Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
1595000
CY2012Q4 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
965000
CY2012Q4 us-gaap Product Warranty Accrual
ProductWarrantyAccrual
1992000
CY2012Q4 us-gaap Deferred Tax Liabilities Deferred Expense Other Capitalized Costs
DeferredTaxLiabilitiesDeferredExpenseOtherCapitalizedCosts
169000
CY2012Q4 us-gaap Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets
DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
9015000
CY2012Q4 us-gaap Liabilities
Liabilities
153883000
CY2012Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
9361000
CY2012Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
100000
CY2012Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
151818000
CY2012Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
4923
CY2012Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
5445000
CY2012Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
4661000
CY2012Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1867000
CY2012Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2012Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
7608000
CY2012Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-481551000
CY2012Q4 us-gaap Assets
Assets
198059000
CY2012Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
13.51
CY2012Q4 us-gaap Deferred Tax Liabilities Noncurrent
DeferredTaxLiabilitiesNoncurrent
700000
CY2012Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
33294000
CY2012Q4 us-gaap Inventory Net
InventoryNet
14867000
CY2012Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2012Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
198059000
CY2012Q4 us-gaap Long Term Debt
LongTermDebt
118159000
CY2012Q4 us-gaap Product Warranty Accrual Noncurrent
ProductWarrantyAccrualNoncurrent
1129000
CY2012Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
17957000
CY2012Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
57293000
CY2012Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
32900000
CY2012Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
48359063 shares
CY2012Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards State And Local
DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal
282800000
CY2012Q4 us-gaap Operating Leases Future Minimum Payments Due Thereafter
OperatingLeasesFutureMinimumPaymentsDueThereafter
CY2012Q4 us-gaap Deferred Finance Costs Noncurrent Net
DeferredFinanceCostsNoncurrentNet
2004000
CY2012Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
2154495 shares
CY2012Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Allowance For Doubtful Accounts
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts
2602000
CY2012Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
19026000
CY2012Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
1487000
CY2012Q4 us-gaap Accounts Receivable Gross Current
AccountsReceivableGrossCurrent
39921000
CY2012Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
2665
CY2012Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
3977
CY2012Q4 us-gaap Liabilities Current
LiabilitiesCurrent
48286000
CY2012Q4 us-gaap Deferred Revenue
DeferredRevenue
5400000
CY2012Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
6627000
CY2012Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2502190 shares
CY2012Q4 us-gaap Common Stock Value
CommonStockValue
48000
CY2012Q4 us-gaap Deferred Tax Liabilities Deferred Expense Deferred Financing Costs
DeferredTaxLiabilitiesDeferredExpenseDeferredFinancingCosts
15955000
CY2012Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2012Q4 us-gaap Interest Payable Current
InterestPayableCurrent
258000
CY2012Q4 us-gaap Taxes Payable Current
TaxesPayableCurrent
3965000
CY2012Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
9937000
CY2012Q4 us-gaap Assets Current
AssetsCurrent
109936000
CY2012Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
11785000
CY2012Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards Domestic
DeferredTaxAssetsOperatingLossCarryforwardsDomestic
404400000
CY2012Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2012Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
171066000
CY2012Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2012Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2012Q4 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
2521000
CY2012Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
27927000
CY2012Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
25422000
CY2012Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
14429000
CY2012Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
525679000
CY2012Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
103730000
CY2012Q4 podd Deferred Tax Assets Depreciation And Amortization
DeferredTaxAssetsDepreciationAndAmortization
2357000
CY2012Q4 podd Deferred Tax Liabilities Gross
DeferredTaxLiabilitiesGross
25278000
CY2012Q4 podd Accrued Training Current
AccruedTrainingCurrent
455000
CY2012Q4 podd Deferred Tax Assets Start Up Costs
DeferredTaxAssetsStartUpCosts
2020000
CY2012Q4 podd Shares Acquired Pursuant To Agreement
SharesAcquiredPursuantToAgreement
3750000 shares
CY2012Q4 podd Number Of Financial Institution
NumberOfFinancialInstitution
2 Location
podd Deferred Income Tax Benefit
DeferredIncomeTaxBenefit
-11339000
CY2009Q3 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
27500000
CY2009Q3 us-gaap Proceeds From Lines Of Credit
ProceedsFromLinesOfCredit
32500000
CY2009Q3 us-gaap Repayments Of Lines Of Credit
RepaymentsOfLinesOfCredit
27500000
CY2009Q3 us-gaap Line Of Credit Facility Frequency Of Payments
LineOfCreditFacilityFrequencyOfPayments
Quarterly
CY2012Q4 podd Number Of Customers With Greater Than Ten Percent Accounts Receivable Balance
NumberOfCustomersWithGreaterThanTenPercentAccountsReceivableBalance
2 Customer
CY2012Q4 podd Accrued Supplier Charges
AccruedSupplierCharges
1752000
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
905000
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.39
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1655000
us-gaap Net Income Loss
NetIncomeLoss
-17930000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-11339000
podd Deferred Income Tax Benefit
DeferredIncomeTaxBenefit
-11339000
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
862000
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.68
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
370000
us-gaap Net Income Loss
NetIncomeLoss
-31492000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-11339000
CY2009Q3 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
2855659 shares
CY2009Q1 invest Investment Warrants Exercise Price
InvestmentWarrantsExercisePrice
3.13
CY2009Q1 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
6100000
CY2009Q1 podd Common Stock Warrants Issued
CommonStockWarrantsIssued
3750000 shares
CY2010Q4 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
47800000
CY2010Q4 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
3450000 shares
CY2010Q4 podd Proceeds From Issuance Of Common Stock Net Of Expenses
ProceedsFromIssuanceOfCommonStockNetOfExpenses
45400000
CY2010 us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-380000
CY2010 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
3800000
CY2010 us-gaap Operating Income Loss
OperatingIncomeLoss
-38633000
CY2010 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
48683000
CY2010 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
11737000
CY2010 us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
32500000
CY2010 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-22526000
CY2010 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
5025000
CY2010 us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
-468000
CY2010 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
5077000
CY2010 us-gaap Share Based Compensation
ShareBasedCompensation
5064000
CY2010 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.0316 pure
CY2010 us-gaap Restructuring Settlement And Impairment Provisions
RestructuringSettlementAndImpairmentProvisions
4431000
CY2010 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
3317000
CY2010 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.54
CY2010 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
53240000
CY2010 us-gaap Restructuring Costs And Asset Impairment Charges
RestructuringCostsAndAssetImpairmentCharges
4432000
CY2010 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-35625000
CY2010 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
11737000
CY2010 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-61159000
CY2010 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-6549000
CY2010 us-gaap Investment Income Interest
InvestmentIncomeInterest
168000
CY2010 us-gaap Income Taxes Paid
IncomeTaxesPaid
11000
CY2010 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
229000
CY2010 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
277000
CY2010 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.0348 pure
CY2010 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
45449000
CY2010 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
6549000
CY2010 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-14722000
CY2010 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
26667000
CY2010 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-381000
CY2010 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
15044000
CY2010 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
3040000
CY2010 us-gaap Sales Revenue Net
SalesRevenueNet
96966000
CY2010 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
5196000
CY2011 us-gaap Investment Income Interest
InvestmentIncomeInterest
139000
CY2010 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
34695000
CY2010 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
16566000
CY2010 us-gaap Effective Income Tax Rate Reconciliation Tax Credits
EffectiveIncomeTaxRateReconciliationTaxCredits
0.0080 pure
CY2010 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
27452000
CY2010 us-gaap Interest And Debt Expense
InterestAndDebtExpense
22694000
CY2010 us-gaap Defined Contribution Plan Employer Matching Contribution Percent
DefinedContributionPlanEmployerMatchingContributionPercent
0.04 pure
CY2010 us-gaap Interest Costs Capitalized
InterestCostsCapitalized
200000
CY2010 us-gaap Operating Expenses
OperatingExpenses
82359000
CY2010 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
1343000
CY2010 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.3400 pure
CY2010 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.2714 pure
CY2010 us-gaap Depreciation
Depreciation
5100000
CY2010 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5000000
CY2010 us-gaap Gross Profit
GrossProfit
43726000
CY2010 us-gaap Interest Paid
InterestPaid
8087000
CY2010 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
100000
CY2010 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
2300
CY2010 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
39607899 shares
CY2010 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7419633 shares
CY2010 us-gaap Net Income Loss
NetIncomeLoss
-61159000
CY2010 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
900000
CY2010 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
0
CY2010 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
9.92
CY2010 podd Increase Decrease In Accounts Payable Accrued Expenses And Other Liabilities
IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities
-1139000
CY2010 podd Effective Income Tax Rate Reconciliation State Apportionment
EffectiveIncomeTaxRateReconciliationStateApportionment
-0.0798 pure
CY2010 podd Defined Contribution Plan Employer Discretionary Match Percentage
DefinedContributionPlanEmployerDiscretionaryMatchPercentage
0.25 pure
CY2010 podd Deferred Income Tax Benefit
DeferredIncomeTaxBenefit
0
CY2011 us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
383000
CY2011 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
8800000
CY2011 us-gaap Operating Income Loss
OperatingIncomeLoss
-42467000
CY2011 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
5460000
CY2011 us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
37855000
CY2011 us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
88195000
CY2011 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-14576000
CY2011 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
7683000
CY2011 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
77000
CY2011 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
8503000
CY2011 us-gaap Share Based Compensation
ShareBasedCompensation
7734000
CY2011 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.0288 pure
CY2011 us-gaap Product Warranty Accrual Payments
ProductWarrantyAccrualPayments
2984000
CY2011 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
3165000
CY2011 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.98
CY2011 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
253000
CY2011 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
85543000
CY2011 us-gaap Stock Issued1
StockIssued1
24432000
CY2011 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.1966 pure
CY2011 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-25452000
CY2011 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-48969000
CY2011 us-gaap Income Taxes Paid
IncomeTaxesPaid
263000
CY2011 us-gaap Product Warranty Accrual Warranties Issued
ProductWarrantyAccrualWarrantiesIssued
3071000
CY2011 us-gaap Effective Income Tax Rate Reconciliation Tax Credits
EffectiveIncomeTaxRateReconciliationTaxCredits
0.0207 pure
CY2011 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
55102000
CY2011 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
21863000
CY2011 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-1665000
CY2011 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
-0.0188 pure
CY2011 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
11114000
CY2011 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-19319000
CY2011 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
44083000
CY2011 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-853000
CY2011 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
9736000
CY2011 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
5242000
CY2011 us-gaap Sales Revenue Net
SalesRevenueNet
152255000
CY2011 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
3617000
CY2011 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-57043000
CY2011 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
43233000
CY2011 us-gaap Adjustments To Additional Paid In Capital Equity Component Of Convertible Debt
AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt
25915000
CY2011 us-gaap Interest And Debt Expense
InterestAndDebtExpense
14715000
CY2011 us-gaap Defined Contribution Plan Employer Matching Contribution Percent
DefinedContributionPlanEmployerMatchingContributionPercent
0.06 pure
CY2011 us-gaap Interest Costs Capitalized
InterestCostsCapitalized
400000
CY2011 us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
946000
CY2011 us-gaap Operating Expenses
OperatingExpenses
109179000
CY2011 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-1879000
CY2011 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.3400 pure
CY2011 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.1165 pure
CY2011 us-gaap Depreciation
Depreciation
4600000
CY2011 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
7700000
CY2011 us-gaap Gross Profit
GrossProfit
66712000
CY2011 us-gaap Interest Paid
InterestPaid
5173000
CY2011 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
700000
CY2011 us-gaap Stock Issued During Period Value Acquisitions
StockIssuedDuringPeriodValueAcquisitions
24188000
CY2011 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
46689880 shares
CY2011 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
-946000
CY2011 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-11289000
CY2011 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
9671568 shares
CY2011 us-gaap Net Income Loss
NetIncomeLoss
-45831000
CY2011 us-gaap Proceeds From Debt Net Of Issuance Costs
ProceedsFromDebtNetOfIssuanceCosts
138783000
CY2011 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
1300000
CY2011 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-11212000
CY2011 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
3900000
CY2011 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
11.75
CY2011 podd Increase Decrease In Accounts Payable Accrued Expenses And Other Liabilities
IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities
4697000
CY2011 podd Defined Contribution Plan Employer Discretionary Match Percentage
DefinedContributionPlanEmployerDiscretionaryMatchPercentage
0.50 pure
CY2012 dei Entity Central Index Key
EntityCentralIndexKey
0001145197
CY2012 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
Yes
CY2011 podd Percentage Of Accounts Payable
PercentageOfAccountsPayable
0.12 pure
CY2011 podd Deferred Income Tax Benefit
DeferredIncomeTaxBenefit
-11289000
CY2012 dei Trading Symbol
TradingSymbol
PODD
CY2012 dei Entity Registrant Name
EntityRegistrantName
INSULET CORP
CY2012 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2012 dei Amendment Flag
AmendmentFlag
false
CY2012 dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
CY2012 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2012 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2012 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2012
CY2012 dei Document Type
DocumentType
10-K
CY2012 dei Document Period End Date
DocumentPeriodEndDate
2012-12-31
CY2012 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2012 us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<div> <p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%"> <font style="FONT-FAMILY: Times New Roman" size="2"><b><i>Restatement of Previously Issued Financial Statements</i></b></font></p> <p style="MARGIN-TOP: 6px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"> <font style="FONT-FAMILY: Times New Roman" size="2">As discussed below and further described in Note 18, the Company restated its financial results for the three and six months ended June&#xA0;30, 2011, the three and nine months ended September&#xA0;30, 2011, the year ended December&#xA0;31, 2011, the three months ended March&#xA0;31, 2012, the three and six months ended June&#xA0;30, 2012, and the three and nine months ended September&#xA0;30, 2012 to correct errors in the accounting for income taxes.</font></p> <p style="MARGIN-TOP: 12px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"> <font style="FONT-FAMILY: Times New Roman" size="2">In June 2011, the Company acquired all of the outstanding shares of privately-held Neighborhood Diabetes and accounted for the acquisition as a business combination. In connection with the acquisition, the Company recognized net deferred tax liabilities of $11.3 million. The Company also reduced its preexisting valuation allowance and goodwill, accordingly, through purchase accounting. Upon subsequent review, the Company determined that the $11.3 million reduction of its preexisting valuation allowance should have been reported as an income tax benefit and not as an adjustment to goodwill. The Company has corrected its statement of operations with respect to the income tax benefit generated as a result of the change in the valuation allowance.</font></p> <p style="MARGIN-TOP: 12px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"> <font style="FONT-FAMILY: Times New Roman" size="2">In June 2011, the Company modified its outstanding convertible debt. Upon subsequent review, the Company determined that at the date of the modification it should have recognized approximately $5.5 million in additional deferred tax liability related to its debt. The recognition of this additional deferred tax liability would have resulted in a corresponding reduction of the Company&#x2019;s preexisting valuation allowance and therefore had no effect on its statement of operations. The Company has corrected certain balance sheet amounts with respect to the presentation of its deferred tax assets and liabilities.</font></p> <p style="MARGIN-TOP: 12px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"> <font style="FONT-FAMILY: Times New Roman" size="2">The restatement resulted in an increase in current deferred tax assets (which are presented as a component of prepaid expenses and other current assets) of $1.2 million at June&#xA0;30, 2011 and September&#xA0;30, 2011 and $0.9 million at December&#xA0;31, 2011, an increase in goodwill of $11.3 million at June&#xA0;30, 2011 and September&#xA0;30, 2011 and $10.9 million at December&#xA0;31, 2011, and an increase in non-current deferred tax liabilities (which are presented as a component of other long-term liabilities) of $1.2 million at June&#xA0;30, 2011 and September&#xA0;30, 2011 and $0.4 million at December&#xA0;31, 2011. The restatement also resulted in an increase in tax benefit of $11.3 million in the three and six months ended June&#xA0;30, 2011, the nine months ended September&#xA0;30, 2011, and the year ended December&#xA0;31, 2011. The restatement had no effect on amounts reported in periods prior to the quarter ended June&#xA0;30, 2011.</font></p> <p style="MARGIN-TOP: 12px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"> <font style="FONT-FAMILY: Times New Roman" size="2">The restatement resulted in an increase in current deferred tax assets (which are presented as a component of prepaid and expenses and other current assets) of $0.9 million at March&#xA0;31, 2012,&#xA0;June&#xA0;30, 2012 and September&#xA0;30, 2012, an increase in goodwill of $10.9 million at March&#xA0;31, 2012,&#xA0;June&#xA0;30, 2012 and September&#xA0;30, 2012, and an increase in non-current deferred tax liabilities (which are presented as a component of other long-term liabilities) of $0.4 million at March&#xA0;31, 2012,&#xA0;June&#xA0;30, 2012, and September&#xA0;30, 2012.</font></p> </div>
CY2012 us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-185000
CY2012 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
9019000
CY2012 us-gaap Operating Income Loss
OperatingIncomeLoss
-35971000
CY2012 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
19.33
CY2012 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
4927000
CY2012 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-15684000
CY2012 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
9862000
CY2012 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
121000
CY2012 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
11030000
CY2012 us-gaap Share Based Compensation
ShareBasedCompensation
9920000
CY2012 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.0138 pure
CY2012 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
15.44
CY2012 us-gaap Acquired Finite Lived Intangible Assets Weighted Average Useful Life
AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
P10Y
CY2012 us-gaap Product Warranty Accrual Payments
ProductWarrantyAccrualPayments
2634000
CY2012 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
3409000
CY2012 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.08
CY2012 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
676819 shares
CY2012 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
119033000
CY2012 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div> <p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%"> <font size="2"><font style="FONT-FAMILY: Times New Roman" size="2"><b><i>Concentration of Credit Risk</i></b></font></font></p> <p style="MARGIN-TOP: 6px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"> <font size="2"><font style="FONT-FAMILY: Times New Roman" size="2">Financial instruments that subject the Company to credit risk primarily consist of cash and cash equivalents. The Company maintains the majority of its cash with two accredited financial institutions.</font></font></p> <p style="MARGIN-TOP: 12px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"> <font size="2"><font style="FONT-FAMILY: Times New Roman" size="2">The Company purchases complete OmniPods from Flextronics International Ltd., its single source supplier. As of December&#xA0;31, 2012 and 2011, liabilities from one vendor represented approximately 19% and 12% of the combined balance of accounts payable and accrued expenses, respectively.</font></font></p> </div>
CY2012 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.0040 pure
CY2012 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-29059000
CY2012 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-10991000
CY2012 us-gaap Investment Income Interest
InvestmentIncomeInterest
110000
CY2012 us-gaap Income Taxes Paid
IncomeTaxesPaid
11000
CY2012 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
392000
CY2012 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
2863000
CY2012 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
6.98
CY2012 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
-0.0118 pure
CY2012 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1 Segment
CY2012 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
10991000
CY2012 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-36662000
CY2012 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
51240000
CY2012 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
898000
CY2012 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
10212000
CY2012 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
4592000
CY2012 us-gaap Sales Revenue Net
SalesRevenueNet
211369000
CY2012 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
13513000
CY2012 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-51655000
CY2012 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
52708000
CY2012 us-gaap Nature Of Operations
NatureOfOperations
<div> <table style="BORDER-COLLAPSE:COLLAPSE" border="0" cellpadding="0" cellspacing="0" width="100%"> <tr> <td width="4%" valign="top" align="left"><font style="font-family:Times New Roman" size="2"><b>1.</b></font></td> <td align="left" valign="top"><font style="font-family:Times New Roman" size="2"><b>Nature of the Business</b></font></td> </tr> </table> <p style="margin-top:6px;margin-bottom:0px; text-indent:4%"> <font style="font-family:Times New Roman" size="2">The Company is primarily engaged in the development, manufacturing and sale of its proprietary OmniPod Insulin Management System (the &#x201C;OmniPod System&#x201D;), an innovative, discreet and easy-to-use insulin infusion system for people with insulin-dependent diabetes. The OmniPod System is the only commercially-available insulin infusion system of its kind. The OmniPod System features a unique disposable tubeless OmniPod which is worn on the body for approximately three days at a time and the handheld, wireless Personal Diabetes Manager (&#x201C;PDM&#x201D;). Conventional insulin pumps require people with insulin-dependent diabetes to learn to use, manage and wear a number of cumbersome components, including up to 42&#xA0;inches of tubing. In contrast, the OmniPod System features only two discreet, easy-to-use devices that eliminate the need for a bulky pump, tubing and separate blood glucose meter, provides for virtually pain-free automated cannula insertion, communicates wirelessly and integrates a blood glucose meter. The Company believes that the OmniPod System&#x2019;s unique proprietary design offers significant lifestyle benefits to people with insulin-dependent diabetes.</font></p> <p style="margin-top:12px;margin-bottom:0px; text-indent:4%"> <font style="font-family:Times New Roman" size="2">To support the sales of the OmniPod System, in June 2011, the Company acquired Neighborhood Holdings, Inc. and its wholly-owned subsidiaries (collectively, &#x201C;Neighborhood Diabetes&#x201D;) in order to expand the Company&#x2019;s full suite diabetes management product offerings and obtain access to a larger number of insulin dependent patients. Through Neighborhood Diabetes, the Company is able to provide customers with blood glucose testing supplies, traditional insulin pumps, pump supplies and pharmaceuticals and has the ability to process claims as either durable medical equipment or through pharmacy benefits.</font></p> <p style="margin-top:12px;margin-bottom:0px; text-indent:4%"> <font style="font-family:Times New Roman" size="2">The U.S. Food and Drug Administration (&#x201C;FDA&#x201D;) approved the original OmniPod System in January 2005, and the Company began commercial sale in the United States in October 2005. The Company received CE Mark approval for the original OmniPod System in April 2009.</font></p> <p style="margin-top:12px;margin-bottom:0px; text-indent:4%"> <font style="font-family:Times New Roman" size="2">The Company has also expanded the availability of the OmniPod System internationally through its partnership with Ypsomed Distribution AG (&#x201C;Ypsomed&#x201D;) and GlaxoSmithKline (&#x201C;GSK&#x201D;). In January 2010, the Company entered into a distribution agreement with Ypsomed pursuant to which Ypsomed became the exclusive distributor of the OmniPod System in multiple countries. In February 2011, the Company entered into a distribution agreement with GSK pursuant to which GSK became the exclusive distributor of the OmniPod System in Canada. The Company has focused its efforts through 2011 and 2012 on the development and regulatory approval of its next generation OmniPod System. In August 2011, the Company received CE Mark approval, and in December 2012, the Company received 510(k) clearance for the next generation OmniPod System by the FDA.</font></p> </div>
CY2012 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
24359000
CY2012 us-gaap Product Warranty Accrual Warranties Issued
ProductWarrantyAccrualWarrantiesIssued
2666000
CY2012 us-gaap Effective Income Tax Rate Reconciliation Tax Credits
EffectiveIncomeTaxRateReconciliationTaxCredits
0.0050 pure
CY2012 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
3388000
CY2012 us-gaap Interest And Debt Expense
InterestAndDebtExpense
15794000
CY2012 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
121552 shares
CY2012 us-gaap Defined Contribution Plan Employer Matching Contribution Percent
DefinedContributionPlanEmployerMatchingContributionPercent
0.06 pure
CY2012 us-gaap Interest Costs Capitalized
InterestCostsCapitalized
600000
CY2012 us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
1539000
CY2012 us-gaap Operating Expenses
OperatingExpenses
128307000
CY2012 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
3029000
CY2012 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.3400 pure
CY2012 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
16700000
CY2012 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.3234 pure
CY2012 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
47924324 shares
CY2012 us-gaap Depreciation
Depreciation
5000000
CY2012 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
9900000
CY2012 us-gaap Gross Profit
GrossProfit
92336000
CY2012 us-gaap Interest Paid
InterestPaid
6197000
CY2012 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
1000000
CY2012 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
-1538000
CY2012 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
91000
CY2012 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
9580353 shares
CY2012 us-gaap Net Income Loss
NetIncomeLoss
-51867000
CY2012 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
1700000
CY2012 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
485970 shares
CY2012 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
212000
CY2012 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0
CY2011Q4 us-gaap Net Income Loss
NetIncomeLoss
-14337000
CY2012 us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%"> <font style="FONT-FAMILY: Times New Roman" size="2"><b><i>Use of Estimates in Preparation of Financial Statements</i></b></font></p> <p style="MARGIN-TOP: 6px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"> <font style="FONT-FAMILY: Times New Roman" size="2">The preparation of financial statements in conformity with generally accepted accounting principles in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenue and expense during the reporting periods. The most significant estimates used in these financial statements include the valuation of stock-based compensation expense, accounts receivable, inventories, deferred revenue, and equity instruments, the lives of property and equipment and intangible assets, as well as warranty and doubtful accounts allowance reserve calculations. Actual results may differ from those estimates.</font></p> </div>
CY2012 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
6000000
CY2012 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
12.04
CY2012 podd Increase Decrease In Accounts Payable Accrued Expenses And Other Liabilities
IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities
2999000
CY2012 podd Product Warranty Term
ProductWarrantyTerm
P4Y
CY2012 podd Return Period
ReturnPeriod
P45D
CY2012 podd Defined Contribution Plan Service Period
DefinedContributionPlanServicePeriod
P30D
CY2012Q4 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.21
CY2012Q4 us-gaap Sales Revenue Net
SalesRevenueNet
57828000
CY2012Q4 us-gaap Gross Profit
GrossProfit
25319000
CY2012Q4 us-gaap Net Income Loss
NetIncomeLoss
-10194000
CY2012 podd Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Forfeitures
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitures
0.16 pure
CY2012 podd Defined Contribution Plan Employer Discretionary Match Percentage
DefinedContributionPlanEmployerDiscretionaryMatchPercentage
0.50 pure
CY2012 podd Percentage Of Accounts Payable
PercentageOfAccountsPayable
0.19 pure
CY2012 podd Deferred Income Tax Benefit
DeferredIncomeTaxBenefit
0
CY2012 podd Expected Decrease In Uncertain Tax Positions
ExpectedDecreaseInUncertainTaxPositions
100000
CY2011Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.22
CY2011Q1 us-gaap Sales Revenue Net
SalesRevenueNet
28258000
CY2011Q1 us-gaap Gross Profit
GrossProfit
13533000
CY2011Q1 us-gaap Net Income Loss
NetIncomeLoss
-9848000
CY2011Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.17
CY2011Q2 us-gaap Sales Revenue Net
SalesRevenueNet
32211000
CY2011Q2 us-gaap Gross Profit
GrossProfit
14538000
CY2011Q2 us-gaap Net Income Loss
NetIncomeLoss
-8084000
CY2011Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-11339000
CY2012Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.31
CY2012Q1 us-gaap Sales Revenue Net
SalesRevenueNet
47754000
CY2012Q1 us-gaap Gross Profit
GrossProfit
20296000
CY2012Q1 us-gaap Net Income Loss
NetIncomeLoss
-14780000
CY2012Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.30
CY2012Q2 us-gaap Gross Profit
GrossProfit
22331000
CY2012Q2 us-gaap Sales Revenue Net
SalesRevenueNet
51035000
CY2010Q4 podd Write Off Of Debt Discounts And Financing Cost
WriteOffOfDebtDiscountsAndFinancingCost
7000000
CY2011Q4 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.30
CY2012Q2 us-gaap Net Income Loss
NetIncomeLoss
-14476000
CY2012Q3 us-gaap Gross Profit
GrossProfit
24390000
CY2012Q3 us-gaap Net Income Loss
NetIncomeLoss
-12417000
CY2011Q4 us-gaap Sales Revenue Net
SalesRevenueNet
47192000
CY2011Q4 us-gaap Gross Profit
GrossProfit
20080000
CY2010Q4 us-gaap Repayments Of Lines Of Credit
RepaymentsOfLinesOfCredit
32500000
CY2010Q4 podd Debt Instrument Year To Date Principal Repayment
DebtInstrumentYearToDatePrincipalRepayment
33300000
CY2010Q4 podd Interest And Prepayment Penalty For Credit Facility
InterestAndPrepaymentPenaltyForCreditFacility
800000
CY2011Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.29
CY2011Q3 us-gaap Sales Revenue Net
SalesRevenueNet
44594000
CY2011Q3 us-gaap Gross Profit
GrossProfit
18561000
CY2011Q3 us-gaap Net Income Loss
NetIncomeLoss
-13562000
CY2012Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.26
CY2012Q3 us-gaap Sales Revenue Net
SalesRevenueNet
54752000

Files In Submission

Name View Source Status
0001193125-13-083670-index-headers.html Edgar Link pending
0001193125-13-083670-index.html Edgar Link pending
0001193125-13-083670.txt Edgar Link pending
0001193125-13-083670-xbrl.zip Edgar Link pending
d454863d10k.htm Edgar Link pending
d454863dex211.htm Edgar Link pending
d454863dex231.htm Edgar Link pending
d454863dex311.htm Edgar Link pending
d454863dex312.htm Edgar Link pending
d454863dex321.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
g454863g42d66.jpg Edgar Link pending
podd-20121231.xml Edgar Link completed
podd-20121231.xsd Edgar Link pending
podd-20121231_cal.xml Edgar Link unprocessable
podd-20121231_def.xml Edgar Link unprocessable
podd-20121231_lab.xml Edgar Link unprocessable
podd-20121231_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R73.htm Edgar Link pending
R74.htm Edgar Link pending
R75.htm Edgar Link pending
R76.htm Edgar Link pending
R77.htm Edgar Link pending
R78.htm Edgar Link pending
R79.htm Edgar Link pending
R8.htm Edgar Link pending
R80.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending